Scope
Reference
CU.1623.RR
Description
Cardiff University's School of Medicine is procuring the manufacture of a novel investigational medicinal product (IMP), Triiodothyronine sulphate (T3S), for use in a Phase 2b clinical trial. The service includes the production of the active pharmaceutical ingredient (API), the IMP, and the finished drug formulation (FDF) in blister packs. This bespoke drug is intended for hypothyroid patients with a specific genetic variation affecting thyroid hormone metabolism. The supplier will manufacture the product to GMP standards, using a validated Route of Synthesis supported by existing preclinical and toxicology data.
Contract 1. LIONNS-D2 Project - Production of T3S API, IMP and FDF
Supplier
Contract value
- 953600.00 EUR excluding VAT
- 953600.00 EUR including VAT
Above the relevant threshold
Award decision date
22 October 2025
Standstill period
- End: 4 November 2025
- 8 working days
Earliest date the contract will be signed
5 November 2025
Contract dates (estimated)
- 6 November 2025 to 31 January 2027
- 1 year, 2 months, 25 days
Main procurement category
Goods
CPV classifications
- 33600000 - Pharmaceutical products
Contract locations
- UKL - Wales
Procedure
Procedure type
Direct award
Supplier
Ardena Holding NV
- Public Procurement Organisation Number: PRMH-6467-WRPY
Kleimoer 4
Mariakerke
9030
Belgium
Email: info@ardena.com
Website: http://www.ardena.com
Small or medium-sized enterprise (SME): No
Voluntary, community or social enterprise (VCSE): No
Supported employment provider: No
Public service mutual: No
Contract 1. LIONNS-D2 Project - Production of T3S API, IMP and FDF
Contracting authority
CARDIFF UNIVERSITY
- Companies House: RC000089
- Public Procurement Organisation Number: PHVT-4343-HWYR
Park Place
Cardiff
CF10 3AT
United Kingdom
Region: UKL22 - Cardiff and Vale of Glamorgan
Organisation type: Public authority - sub-central government
Devolved regulations that apply: Wales